{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023217","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.764438+00:00","generated_at":"2026-06-22T04:01:44.622324+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Frequency Therapeutics completes FX-322 Phase 2b enrollment; Q3 net loss $19.5M, cash $99.3M","bullets":["Phase 2b study of FX-322 for SNHL enrolled 142 participants; primary endpoint readout expected Q1 2023.","Second hearing restoration program FX-345 to begin Phase 1b in coming weeks; H2 2023 results expected.","MS remyelination program advanced to IND-enabling studies; IND filing planned for H2 2023.","Q3 2022 net loss $19.5M vs $25.2M in Q3 2021; R&D expenses $11.7M, down from $15.7M.","Cash, equivalents and marketable securities $99.3M; expected to fund operations into 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023217","json":"https://secwatch.observer/filing/0000950170-22-023217.json","markdown":"https://secwatch.observer/filing/0000950170-22-023217.md","text":"https://secwatch.observer/filing/0000950170-22-023217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017022023217/0000950170-22-023217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017022023217/freq-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:01:44.622324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e340f693a4725f0b30181d518af3f86a4cbc5330","claim":"Korro Bio, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017022023217/0000950170-22-023217-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}